Julian Chick of Admedus has advised that the Company anticipates receiving the HSV-2 trial data sets from “third parties” soon and that by the end of February, there will be released to the market, some interim data on safety and efficacy.
The trial is taking longer than initially intended, partly a consequence of the enrollment of > 40 patients. At this stage 25% of participants have completed their 6 month booster.
The Company is very mindful, it would appear, of what data it can release without compromising the integrity of the trial and at the same time respecting the shareholder and interested parties.
Admedus continues to monitor patients and further data and assessments will be released to the market later in the year.
Pending HSV 2 results
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
-0.200(1.09%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| $18.50 | $18.50 | $18.00 | $77.59K | 4.263K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 206 | $18.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.70 | 34 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |